Adipose-derived Stem Cells (ADSCs) for Moderate to Severe Chronic Kidney Disease
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
1. To assess the safety of allogeneic injection of expanded ADSCs to patients with Moderate
to Severe Chronic Kidney Disease
2. To assess the efficacy of allogeneic injection of expanded ADSCs to patients with
Moderate to Severe Chronic Kidney Disease